School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region.
J Pharm Biomed Anal. 2012 Jan 25;58:83-93. doi: 10.1016/j.jpba.2011.09.020. Epub 2011 Sep 22.
Loxapine represents an interesting example of old "new" drug and is recently drawing attention for its novel inhalation formulation for the treatment of both psychiatric and non-psychiatric disorders. It is extensively metabolized to several active metabolites with diverging pharmacological properties. To further pursue the contribution of metabolites to the overall outcome after loxapine administration, quantification of both loxapine and its active metabolites is essential. The current study developed a rapid liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous quantification of loxapine and its five metabolites (amoxapine, 7-hydroxy-loxapine, 8-hydroxy-loxapine, 7-hydroxy-amoxapine and 8-hydroxy-amoxapine) in rat brain tissues, plasma and cerebrospinal fluid (CSF). By evaluating the effects of perchloric acid and methanol on analyte recovery, the extraction methods were optimized and only small amounts of sample (100 μl for plasma and less than 100mg for brain tissue) were required. The lower limits of quantification (LLOQs) in brain tissue were 3 ng/g for loxapine and amoxapine and 5 ng/g for the four hydroxylated metabolites of loxapine. The LLOQs were 1 ng/ml for loxapine and amoxapine and 2 ng/ml for the four hydroxylated metabolites in plasma, and 10 ng/ml for all analytes in CSF. The developed method was applied to a pharmacokinetic study on rats treated with a low-dose loxapine by oral administration. Four hours after loxapine dosing, high levels of 7-hydroxy-loxapine were found throughout the ten brain regions examined (68-124 ng/g), while only trace amount of loxapine was measured in brain (<5 ng/g) and plasma (<3 ng/ml). The method provides a useful tool for both preclinical and clinical investigations on the dispositions of loxapine and its metabolites, which would help to elucidate their roles in neurotherapeutics.
氯氮平是一种很有趣的老药新用范例,最近因其新型吸入制剂在治疗精神和非精神疾病方面引起了关注。它广泛代谢为几种具有不同药理学特性的活性代谢物。为了进一步研究氯氮平给药后代谢物对整体结果的贡献,定量检测氯氮平和其活性代谢物是必不可少的。本研究开发了一种快速液相色谱-串联质谱(LC-MS/MS)法,用于同时定量检测大鼠脑组织、血浆和脑脊液(CSF)中的氯氮平和其五种代谢物(阿莫沙平、7-羟基氯氮平、8-羟基氯氮平、7-羟基阿莫沙平和 8-羟基阿莫沙平)。通过评估高氯酸和甲醇对分析物回收率的影响,优化了提取方法,仅需少量样品(血浆 100 μl,脑组织少于 100mg)。脑组织中氯氮平和阿莫沙平的定量下限(LLOQ)分别为 3ng/g 和 5ng/g,四种 8-羟基氯氮平的 LLOQ 均为 5ng/g。血浆中氯氮平和阿莫沙平的 LLOQ 分别为 1ng/ml 和 2ng/ml,四种 8-羟基氯氮平的 LLOQ 均为 2ng/ml,CSF 中所有分析物的 LLOQ 均为 10ng/ml。该方法应用于大鼠口服低剂量氯氮平的药代动力学研究。氯氮平给药后 4 小时,在检测的 10 个脑区中均发现 7-羟基氯氮平水平较高(68-124ng/g),而脑组织中氯氮平含量较低(<5ng/g),血浆中氯氮平含量更低(<3ng/ml)。该方法为氯氮平和其代谢物的临床前和临床研究提供了一种有用的工具,有助于阐明其在神经治疗中的作用。